Watertown-based Tetraphase Pharmaceuticals said Tuesday it plans to seek FDA approval for one of its antibiotics early next year after the drug succeeded in a late-stage trial.
Tetraphase (Nasdaq: TTPH) said the antibiotic, called eravacycline, was at least as effective as a commonly-prescribed antibiotic in treating complicated, intra-abdominal infections. There were no serious side effects observed in the 500-patient trial, the company said.
Based on the results, Tetraphase, which had 66 employees…
Watertown-based Tetraphase Pharmaceuticals said Tuesday it plans to seek FDA approval for one of its antibiotics early next year after the drug succeeded in a late-stage trial.
Tetraphase (Nasdaq: TTPH) said the antibiotic, called eravacycline, was at least as effective as a commonly-prescribed antibiotic in treating complicated, intra-abdominal infections. There were no serious side effects observed in the 500-patient trial, the company said.
Based on the results, Tetraphase, which had 66 employees…